GLP1R and type 2 diabetes mellitus: Meta-analyses of clinical trials of GLP-1 receptor agonists showed a reduction in fasting triacylglycerol and total cholesterol and LDL-cholesterol concentrations in type 2 diabetes, while concentrations of HDL-cholesterol were unchanged (Fig. 5a,d) [50].